SCHEMBL2669414

SCHEMBL2669414

COc1ccc(Oc2cccc3c(N)c4c(nc23)CN(C2CC2)C4=O)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA2 P42262 1/20 0.39
▸ NPY1R P25929 1/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ POLB P06746 3/20 0.37
▸ BCHE P06276 6/20 0.37
▸ ACHE P22303 6/20 0.37
▸ GRIN1 Q05586 4/20 0.37
▸ GRIN2A Q12879 4/20 0.37
▸ GRIN2B Q13224 4/20 0.37
▸ CRHBP P24387 1/20 0.35
▸ CRHR2 Q13324 1/20 0.35
▸ NPBWR1 P48145 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA2 P47869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660939 0.84 PDE5A (0.43) BCHEACHEGRIN1GRIN2AGRIN2B
SCHEMBL2661576 0.83 CRHR1 (0.41) NPY1RNPY5RPOLBMAPTGABRG2
SCHEMBL4912799 0.83 GABRG2 (0.49) NPY1RNPY5RPOLBGABRG2GABRB3
SCHEMBL4922297 0.82 NPY1R (0.43) NPY1RNPY5RACHEMAPTLMNA
SCHEMBL2661489 0.81 NPY1R (0.40) NPY1RNPY5RGABRG2GABRB3GABRA2
SCHEMBL2657321 0.80 NPY1R (0.40) NPY1RNPY5RGABRG2GABRB3GABRA2
SCHEMBL2669415 0.80 GABRG2 (0.43) NPY1RNPY5RPOLBKCNH2HRH3
SCHEMBL2669562 0.80 GABRG2 (0.51) NPY1RNPY5RPOLBGABRG2GABRB3
SCHEMBL2659973 0.80 GABRG2 (0.49) NPY1RNPY5RPOLBMAPTGABRG2
SCHEMBL2662080 0.80 GABRG2 (0.43) NPY1RNPY5RPOLBKMT2AGABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GRIA2 301/4885NPY1R 126/4885NPY5R 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback